Minimal Hepatic Encephalopathy
17
1
1
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.9%
1 terminated out of 17 trials
92.3%
+5.8% vs benchmark
24%
4 trials in Phase 3/4
8%
1 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (17)
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
Psychometric Hepatic Encephalopathy Score in Prediction of Minimal Hepatic Encephalopathy in Compensated Cirrhotic Patients
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
A Study of MHE in Patients With Liver Diseases
HEAL STUDY (Hepatic Encephalopathy and Albumin Study)
Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy
Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation
Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
Study of Lactulose in Children With Chronic Liver Disease
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
Study of Rifaximin in Minimal Hepatic Encephalopathy
Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy
A Nutritional Approach to Minimal Hepatic Encephalopathy
Effect of Yogurt on Minimal Hepatic Encephalopathy
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life